髙原 健

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Urinary Bladder Neoplasms 93%
3. Renal Cell Carcinoma 75%
4. Urinary Bladder 59%
5. Survival 51%
6. Castration 50%
7. Nephrectomy 44%
8. Cystectomy 40%
9. Neoplasms 38%
10. Carcinoma 35%
11. Prostate-Specific Antigen 33%
12. Neoplasm Metastasis 32%
13. Therapeutics 30%
14. Androgens 30%
15. Prostate 29%
16. Nephroureterectomy 29%
17. Radiation 29%
18. Japan 26%
19. abiraterone 26%
20. pembrolizumab 24%
21. Recurrence 22%
22. Propensity Score 21%
23. Molecular Targeted Therapy 21%
24. Heterografts 20%
25. Antineoplastic Agents 20%
26. Cisplatin 20%
27. MDV 3100 19%
28. Prostatectomy 19%
29. C-Reactive Protein 18%
30. Growth 18%
31. Albumins 17%
32. Renal Dialysis 17%
33. MicroRNAs 17%
34. Drug Therapy 16%
35. Boron Neutron Capture Therapy 16%
36. cabazitaxel 16%
37. Hormones 15%
38. Urinary Tract 15%
39. Kidney 14%
40. Lymph Nodes 14%
41. Intravesical Administration 14%
42. Transurethral Resection of Prostate 14%
43. Nivolumab 14%
44. Progression-Free Survival 13%
45. Insulin-Like Growth Factor I 13%
46. Androgen Receptors 12%
47. Cell Proliferation 12%
48. Neutrophils 11%
49. Multivariate Analysis 11%
50. Apoptosis 11%